For Research Use Only. Not for Human or Veterinary Use.
Overview
SS-31 — also known as Elamipretide (MTP-131) — is a mitochondria-targeted tetrapeptide that selectively binds cardiolipin, a phospholipid of the inner mitochondrial membrane that is essential for cristae structure and for the assembly of the electron-transport chain. By stabilising this membrane it is studied for improving mitochondrial bioenergetics and reducing reactive-oxygen-species production in models of aging, ischemia–reperfusion injury and mitochondrial disease.
SS-31 is a cell-permeable peptide that concentrates at the inner mitochondrial membrane by binding cardiolipin. Cardiolipin holds the cristae folds and the respiratory supercomplexes together, so stabilising it is studied for restoring efficient electron transport, lowering superoxide leakage and improving ATP production.
Component
Detail
Primary target
Cardiolipin in the inner mitochondrial membrane
Binding mode
Electrostatic + hydrophobic interaction with cardiolipin
Electron transport
Studied for stabilising complex I / III–IV supercomplexes
Bioenergetic support and oxidative-stress reduction
💊Pharmacology
Parameter
Value
Half-life (t½)
≈ 2–4 h (SC); ~30–60 min (IV)
Bioavailability (SC)
≈ 60–80% (estimated)
Tmax
≈ 30–60 min (SC)
Protein binding
≈ 90% (albumin)
Metabolism
Minimal hepatic; proteolytic degradation
Route of administration
Subcutaneous, intravenous (research)
Elimination
Renal (unchanged and fragments)
📚Research Evidence
SS-31 has an extensive preclinical literature and has been taken into clinical trials for mitochondrial disorders. Representative studies and trial programs are named below; specific numerical outcomes are not restated here as claims.
Preclinical model
Research focus
Reference
Aged mouse muscle
Mitochondrial respiration and oxidative stress
Siegel MP, et al.
Cardiac ischemia–reperfusion
Infarct size and mitochondrial function
Szeto HH / Dai DF, et al.
Kidney-injury models
Mitochondrial protection
Birk AV, et al.
Clinical program
Phase
Research focus
Reference
MMPOWER-2 / 3
Phase 2–3
Primary mitochondrial myopathy
Stealth BioTherapeutics
EMBRACE
Phase 2
Heart failure
Stealth BioTherapeutics
RePOWER / TAZPOWER
Phase 2
Barth syndrome
Stealth BioTherapeutics
Representative reported directions from the literature (qualitative; GLP-1 entries reflect published clinical-trial results, others are reported study directions, not restated as precise product claims):
For laboratory research use only. Not for human or veterinary use, diagnosis, or therapeutic application. Descriptions refer to published research contexts and are not medical or product claims.
⚗️Dosing & Reconstitution Reference
Reconstitution and handling parameters for laboratory research. Not dosing guidance for human use.
Parameter
Reference value
Research dose range (literature)
≈ 0.5–2 mg daily (SC), in study protocols
Reconstitution solvent
Bacteriostatic water (0.9% benzyl alcohol)
Final concentration
≈ 2.5–5 mg/mL
Storage (lyophilized)
−20°C, protected from light
Storage (reconstituted)
2–8°C, up to ~7 days
Do not use
If the solution is cloudy or contains particulates
🛡️Safety Profile
Published research observations, provided for reference only. This material is not for human or veterinary use.
Category
Published observations
Local tolerability
Injection-site reactions reported
GI
Mild nausea in some studies
Cytotoxicity
No cytotoxicity observed
Cardiovascular
Generally well tolerated in reported studies
Status
For research use only; not for human or veterinary application
📐Physicochemical Properties
Property
Value
Physical state
White to off-white lyophilized powder
Solubility (water)
Freely soluble (> 100 mg/mL)
logP (octanol/water)
≈ −3.5 (hydrophilic)
Character
Basic tetrapeptide (D-Arg, Lys)
pH (reconstituted)
5.0–6.0
Stability (lyophilized)
≥ 24 months at −20°C
🏭Synthesis & Manufacturing
SS-31 is a short C-terminally amidated tetrapeptide made by Fmoc solid-phase synthesis. The non-standard residues — D-arginine and 2′,6′-dimethyltyrosine (Dmt) — are the parts that require dedicated building blocks.
Step
Detail
Strategy
Fmoc solid-phase peptide synthesis
Resin
Rink amide MBHA resin (C-terminal amide)
Special residues
D-Arg and Dmt (dimethyltyrosine) building blocks
Coupling
HBTU / HOBt with DIPEA
Cleavage
TFA / TIPS / H₂O (95 : 2.5 : 2.5)
Purification
Preparative RP-HPLC (C18, TFA/ACN gradient)
Notes: coupling efficiency and complete Fmoc removal are monitored each cycle; hindered or repeated residues (e.g. Arg-Arg) may need double coupling.
Preparative RP-HPLC removes deletion and truncation impurities to reach research-grade purity; salt exchange (lyophilization from dilute HCl) removes residual TFA/acetate.
Critical quality attributes: correct molecular weight and low deletion-peptide content. Confirm the non-standard residues (D-arginine and 2′,6′-dimethyltyrosine) by chiral / amino-acid analysis.
🔎Analytical Methods
Method
Parameter
Typical result
RP-HPLC (C18, UV 214 nm)
Purity
≥ 98%
HPLC retention
C18, low-organic TFA/ACN gradient
Single main peak
ESI-MS (positive mode)
Identity / mass
[M+H]⁺ ≈ 640 Da
MALDI-TOF
Mass confirmation
[M+H]⁺ ≈ 640 Da
Amino-acid analysis
Composition
Consistent with the stated sequence
LC-MS (extracted ion)
Deletion-peptide impurities
Within specification
Karl Fischer
Water content
< 6%
LAL assay
Endotoxin
Within specification
Ion chromatography
Residual TFA
< 500 ppm
Representative RP-HPLC purity method:
Column: C18, 5 µm, 250 × 4.6 mm
Mobile phase A: 0.1% TFA in water · Mobile phase B: 0.1% TFA in acetonitrile
Confirmatory LC-MS: ESI positive mode ([M+H]⁺ ≈ 640 Da). Confirm the non-standard residues (D-arginine and 2′,6′-dimethyltyrosine) by chiral / amino-acid analysis.
📈Stability Data
Representative stability behaviour under common storage, handling and formulation conditions.
Condition
Duration
Result
Lyophilized, −20°C, dark
≥ 24 months
No significant degradation (purity > 97%)
Lyophilized, 2–8°C, dark
≥ 12 months
Minimal degradation (purity > 95%)
Lyophilized, 25°C (accelerated)
3 months
< 5% degradation
Reconstituted, 2–8°C, dark
7–14 days
Minor degradation
Reconstituted, 25°C
24–48 h
Use promptly
Light exposure (ICH Q1B)
1.2 M lux·h
Generally light-stable
Freeze–thaw (−20°C ⇄ 25°C)
3 cycles
Acceptable — aliquot to avoid repeats
Keep lyophilized powder cold, dry and light-protected; keep any solution refrigerated and protected from light.
Minimise freeze-thaw cycles; aliquot material used across many sessions.
Key factor: Confirm the non-standard residues (D-arginine and 2′,6′-dimethyltyrosine) by chiral / amino-acid analysis.
📖Selected References
Szeto HH. First-in-class cardiolipin-protective compound as a therapeutic agent to restore mitochondrial bioenergetics. British Journal of Pharmacology.
Siegel MP, et al. Mitochondrial-targeted peptide rapidly improves mitochondrial energetics and skeletal muscle performance in aged mice. Aging Cell.
Birk AV, et al. The mitochondrial-targeted compound SS-31 re-energizes ischemic mitochondria by interacting with cardiolipin. Journal of the American Society of Nephrology.
✅Quality & Supply
HPLC ≥ 98% purity with a Certificate of Analysis per batch
Identity confirmed by LC-MS; special residues (D-Arg, Dmt) verified
Research samples through to bulk, with worldwide delivery